We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
27
Oct 2026
NEC Corporation today announced its participation in PREPAIR VAC, a Horizon Europe–funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design.
27
Oct 2026
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, announced the adoption of multiple Reveos™ Automated Blood Processing Systems by Ribeirão Preto Blood Center, the high-volume blood network supporting about 120,000 transfusions a year in São Paulo.
27
Oct 2026
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide - a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
27
Oct 2026
A Mayo Clinic study published in the Journal of Neuro-Oncology suggests that analyzing DNA in cerebrospinal fluid could provide another source of information when MRI cannot provide a clear brain tumor diagnosis or obtaining tissue through biopsy is difficult or potentially unsafe.